FFRDC MOONSHOT PORTFOLIO TASK ORDER - COPTR (DCP)

癌症登月计划旨在加快癌症的预防、诊断和治疗工作，并在5年内实现10年的进步。相关的症状管理研究蓝带小组（BRP）确定了在收集患者报告的症状数据和使用这些数据为决策提供信息和改善临床管理方面进行战略投资的必要性。具体而言，BRP指出，经过验证的患者报告措施（pro）已经导致了系统收集患者报告的症状和功能状态方面的进展。然而，这些进步并非在所有人群中均匀发生，特别是在少数民族和服务不足的人群中。此外，这些人群往往在治疗上有明显的延误，经历更严重的副作用，更有可能不坚持治疗，并且很少有机会获得控制其副作用的补救措施。因此，他们的生活质量、功能、工作和家庭关系受损的风险很高。在这些少数民族和服务不足的人群中，可以发现越来越多的非英语或英语水平较低的人。虽然专家小组指出，需要从服务不足的人群中系统地收集PRO数据，但如果没有足够和适当的PRO问卷翻译，非英语和英语水平低的患者仍将被边缘化，治疗不足，在临床试验中的代表性不足。

The Cancer MoonshotSM was designed to accelerate efforts to prevent, diagnose, and treat cancer and achieve 10 years of progress in 5 years. The associated Symptom Management Research Blue Ribbon Panel (BRP) identified the need for strategic investment in the collection of patient-reported symptom data and the use of that data to inform decision-making and improve clinical management. Specifically, the BRP noted that validated patient-reported measures (PROs) have led to advances in the systematic collection of patient-reported symptoms and functional status. However, these advances have not occurred uniformly across all populations, particularly among minority and underserved populations. Furthermore, these populations often have significant delays in treatment, experience worse side effects, are more likely to be nonadherent to treatment, and have less access to remedies to control their side effects. Consequently, they are at high risk for impaired quality of life, functionality, working, and family relationships. Within this population of minority and underserved can be found a growing number of non-English or low-English proficient speaking individuals. While the Panel noted that systematically gathered PRO data from underserved populations are needed, without adequate and appropriate translations of PRO questionnaires, non-English and low-English proficient patients will remain marginalized, undertreated, and underrepresented in clinical trials. While most of general quality of life questionnaires and the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) are translated in multiple languages, some gaps remain. In addition, protocols often include ancillary non-validated materials (e.g., patient diaries,instructions) that are typically only available in English. Finally, neurocognitive tests are frequently used in both adult and pediatric trials and the lack of translations limits participation of non-English speakers. Thus, this Moonshot effort is intended to improve accrual of Spanish and French speakers to the NCORP clinical trial portfolio by ensuring the availability of the necessary translated materials. The NCI Community Oncology Research Program (NCORP) is a national NCI-supported network that designs and conducts cancer prevention, supportive care and symptom management, screening, and surveillance clinical trials. The NCORP is housed in the NCI Division of Cancer Prevention and collaborates with numerous other NCI Divisions and Offices. NCORP is comprised of 7 Research Bases and 46 Community Sites, 14 of which are designated as Minority/Underserved Community Sites. The NCORP Research Bases are hubs for the network that design and spearhead the conduct of multi-center clinical trials and provide overall administration, data management, scientific and statistical leadership, operational processes and personnel, and regulatory compliance. The NCORP Community Sites accrue participants to NCI-approved cancer clinical trials and research studies. The Sites are consortia of researchers, public hospitals, physician practices, academic medical centers, health systems and other groups that provide healthcare services in communities across the U.S.